Bom preço.  on-line

detalhes dos produtos

Created with Pixso. Para casa Created with Pixso. produtos Created with Pixso.
Medicamentos contra o Câncer de Pulmão
Created with Pixso. Jascayd Nerandomilast 18mg Tablets For Idiopathic Pulmonary Fibrosis And Progressive Pulmonary Fibrosis Intervention

Jascayd Nerandomilast 18mg Tablets For Idiopathic Pulmonary Fibrosis And Progressive Pulmonary Fibrosis Intervention

Marca: Boehringer Ingelheim
Número do modelo: Comprimidos revestidos por película de 18 mg
Quantidade mínima: 1 peça
preço: Please contact a specialist WhatsApp:55342706
Prazo de entrega: Negociável
Condições de pagamento: Western Union, MoneyGram, T/T.
Informações pormenorizadas
Lugar de origem:
EUA
Certificação:
FDA NDA 218764
Especificação:
18mg*60 comprimidos/caixa
Indicações:
Fibrose pulmonar idiopática, fibrose pulmonar progressiva
Alvo:
PDE4B
Nome do produto:
Nerandomilaste
Recomende:
Por favor, siga os conselhos do médico.
Armazenar:
Armazenar entre 20°C e 25°C, permitindo variações de temperatura ambiente entre 15°C e 30°C, manter
Temperatura de armazenamento:
20°C a 25°C
Faixa de temperatura ambiente:
15°C a 30°C
Forma farmacêutica:
Comprimido revestido por película
Força do comprimido:
18 mg
Tamanho do pacote:
60 tabuletas/caixa
Enzima alvo:
PDE4B
Detalhes da embalagem:
Negociável
Habilidade da fonte:
Negociável
Destacar:

Jascayd Nerandomilast 18mg Idiopathic Pulmonary Fibrosis

,

Generic Nerandomilast 18mg Progressive Pulmonary Fibrosis

,

Jascayd BI 1015550 IPF PPF Tablets

Descrição do produto
Jascayd Nerandomilast for Idiopathic Pulmonary Fibrosis & Progressive Pulmonary Fibrosis Intervention
Product Overview

For professional medical use only under physician supervision

Manufacturer: Boehringer Ingelheim International GmbH

Generic Name: Nerandomilast

Brand Name: Jascayd

FDA Approval: NDA 218764

Indications

Jascayd is a highly selective PDE4B targeted inhibitor with anti-fibrotic and immunomodulatory effects. It is indicated for adult patients diagnosed with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). May be used alone or in combination with standard anti-fibrotic agents such as pirfenidone or nintedanib to reduce lung capacity decline and delay disease progression.

Dosage and Administration

Standard Maintenance Dose: 18 mg orally twice daily, 12 hours apart. Swallow whole with room temperature water, before or after meals. Do not split, chew, or crush tablets.

  • Mild/Moderate Hepatic Impairment (Child-Pugh A/B): No dose adjustment required
  • Severe Hepatic Impairment & End-Stage Renal Disease: Insufficient safety data - not recommended

Missed Dose: Take immediately if remembered on the same day. If less than 4 hours until next dose, skip the missed dose. Do not take double dose.

Specifications

Film-coated oral tablets: 18 mg per tablet, 60 tablets per box

Contraindications
  • Patients with severe hypersensitivity to nerandomilast or any excipient component
  • Pregnant and breastfeeding women without professional risk-benefit assessment
Warnings and Precautions
  • Gastrointestinal Effects: Mild diarrhea, nausea, and stomach discomfort common during early treatment. Persistent severe GI reactions require medical evaluation and dose adjustment
  • Liver Function Monitoring: Regular liver function tests recommended during long-term use to monitor transient transaminase elevations
  • Drug Interactions: Metabolized by hepatic oxidation. Professional dose assessment required when used with strong CYP3A modulators
  • Fertility Considerations: Effective contraception recommended for patients of reproductive potential throughout treatment
Common Adverse Reactions (≥5% incidence)

Diarrhea, nausea, headache, fatigue, decreased appetite. Transient liver enzyme abnormalities frequently observed in laboratory tests.

Storage Requirements

Store at 20°C-25°C. Temporary exposure to 15°C-30°C acceptable. Protect from light. Keep in original packaging until use.